Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A2 | O95436 | 1/20 | 0.61 |
| ▸ | BRAF | P15056 | 5/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.36 |
| ▸ | RAF1 | P04049 | 2/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TEK | Q02763 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15432716 | 0.99 | SLC34A2 (0.62) | SLC34A2BRAFROCK2RAF1ROCK1 | |
| SCHEMBL16355204 | 0.94 | SLC34A2 (0.53) | SLC34A2BRAFROCK2RAF1ROCK1 | |
| SCHEMBL15432720 | 0.93 | SLC34A2 (0.54) | SLC34A2BRAFROCK2RAF1ROCK1 | |
| SCHEMBL47036 | 0.93 | SLC34A2 (0.63) | SLC34A2BRAFROCK2RAF1ROCK1 | |
| SCHEMBL15421013 | 0.91 | SLC34A2 (0.61) | SLC34A2BRAFROCK2RAF1ROCK1 | |
| SCHEMBL46963 | 0.88 | SLC34A2 (0.54) | SLC34A2BRAFROCK2RAF1ROCK1 | |
| SCHEMBL18482253 | 0.87 | SLC34A2 (0.52) | SLC34A2BRAFROCK2RAF1ROCK1 | |
| SCHEMBL46804 | 0.87 | SLC34A2 (0.61) | SLC34A2BRAFROCK2RAF1ROCK1 | |
| SCHEMBL39793 | 0.87 | SLC34A2 (0.52) | SLC34A2BRAFROCK2RAF1ROCK1 | |
| SCHEMBL46796 | 0.87 | SLC34A2 (0.52) | SLC34A2BRAFROCK2RAF1ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9301951-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2015-06-18 | — | — | US | disclosed |
| US-8916569-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2014-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | SLC34A2 1/4885BRAF 3436/4885ROCK2 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.